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DNA Vaccines And HIV / AIDS
Ricardo Belmontes, James Ham, Ricardo Paz, Emily Scott-Solomon
Advisors: Professors Jill Rulfs and Helen G. Vassallo
Trial Areas: Lesotho and the United States
United States 
•Developed nation
•Unstable economic and politics minimized
•Focus can be made on effectiveness of vaccine
Lesotho
•270,000 people infected with AIDS (23.2% of population)
•Relatively small area (11.720 sq miles)
•Presence of Riders for Health
•Variety of variables stereotypical of developing nations
Over 33 Million People Live with HIV/AIDS Worldwide
HIV is a retrovirus that infects T-cells which are central in adaptive 
immunity. It enters a cell by attaching to the CD4 receptor and the 
CXCR4 or CCR5 co-receptor. The HIV infection causes the body to 
lose cell immunity. The current treatment for HIV/AIDS, a triple 
cocktail which combines protease and reverse transcriptase 
inhibitors, costs about $10,000-$15,000 a year. However, the 
protease inhibitors increase the risk of cardiovascular disease and 
sudden heart failure in middle-aged HIV/AIDS patients. 
Problem Statement
HIV / AIDS affects over 33 million people worldwide, with the 
greatest number of victims located in developing countries. 
Conventional drugs only ease symptoms and do not cure the 
disease. A DNA vaccination that knocks down the CCR-5 gene 
could offer a solution to the disease.
DNA Vaccines
A DNA vaccine works by directly injecting DNA into the body, either 
the muscle or skin. Carrying the genetic information required, it 
begins producing antigens inside a host cell which will lead to a cell-
mediated immune response. The plasmid DNA vaccine carries the 
genetic code for a piece of pathogen antigen and transcribes it to 
the nucleus. The mRNA is translated into protein and then into 
peptides. The cytotoxic CD 8+ lymphocytes bind to the peptides and 
induce the cell-mediated immune response. 
Great Problems Seminar: 
Heal The World
Creating the Vaccine: Funding
While the cost of delivering a DNA vaccine to a patient is cheap, 
the initial discovery cost of the vaccine is in the millions. 
In 2000, contemporary pharmaceutical companies estimated the 
cost of creating a new drug was $403 million.
Two potential HIV / AIDS vaccine trials were scheduled, estimated 
to cost $140 million and $63 million dollars. In order to create a 
vaccine, additional funding would be needed from outside sources:
•The Bill and Melinda Gates Foundation
•Private foundations
•Universities and research centers
•National Institute for Health (NIH): 
•Estimated budget in 2008 is $2,905,219,000 with 
$596,195,000 allocated for AIDS/HIV research.
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Data Reason
Name • Determine if patients completed treatment and 
retuned for follow ups
Housing Location • Environmental factors that contribute to spread of 
disease
• Area in need of alternative distribution method
Blood Test 
Results
• Check HIV virus level
Dietary Habits • Nutrition Level
Clinical Visitation 
Dates
• Followed inoculation regiments (grace periods 
between treatments)
Age • Determine most susceptible population to target
• Most treatment responsive age 
Gender • Check for gender specific side effects
Economic Status 
(Income)
• Determine most susceptible population to target
• Determine price range affordable
Family History 
(if Available)
Patient Health 
History
• Determine potential genetic diseases
• Other diseases that could be attributed to death if 
occurs
• Determine progression of HIV/AIDS in system
Allergies • Cease distribution to patient to avoid 
hyperimmune response
Prescriptions • Determine if certain medications heighten 
vaccination response
• Determine if certain medications increase health 
risks
Assessment:
